Fintel reports that on November 18, 2024, HSBC upgraded their outlook for Moderna (NasdaqGS:MRNA) from Hold to Buy. Analyst ...

US stocks finished mixed on Monday ahead of a busy week for corporate earnings, though the Nasdaq managed to push higher, led by gains from Tesla.

(Bloomberg) — Asian equities are poised to track Wall Street stocks higher as Treasuries halted a selloff that drove 10-year yields near 4.5%. Traders were also closely watching news around ...

Live Updates Stocks on the Move Today 9:49 am Here are some notable stocks on the move today: Super Micro Computer: The ...

Last week, some large European and U.S. vaccine maker stocks fell in reaction to Robert F. Kennedy Jr.’s nomination to lead ...

Stocks rebounded after last week’s slide as Treasuries stabilized after 10-year yields approached 4.5%, with traders keeping ...

That includes Big Tech, which is currently making a series of peculiar investments in a few strange companies. This has nothing to do with tech. At least on the surface … Yet, these strange ...

Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to Buy while trimming the target price to $58 from $82.

CNBC's Jim Cramer reports on the latest news regarding Moderna. This Insane Timelapse From Hubble Will Change Your ...

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

HSBC analyst Yifeng Liu upgraded Moderna (MRNA) to Buy from Hold with a price target of $58, down from $82. The recent share price weakness ...

Stocks edged higher after their worst week since early September as the selloff in Treasuries abated, with traders keeping a close eye on news around President-elect Donald Trump’s administration.